DENVER, Sept. 14 /PRNewswire/ -- Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor development. These findings were presented by Dr. Michael Whyte at the 31(st) Annual Meeting of the American Society for Bone and Mineral Research in Denver, CO.
